TY - JOUR AU - Manning, G. AU - Plowman, G. D. AU - Hunter, T. AU - Sudarsanam, S. PY - 2002 DA - 2002// TI - Evolution of protein kinase signaling from yeast to man JO - Trends Biochem Sci VL - 27 UR - https://doi.org/10.1016/S0968-0004(02)02179-5 DO - 10.1016/S0968-0004(02)02179-5 ID - Manning2002 ER - TY - JOUR AU - Paul, M. K. AU - Mukhopadhyay, A. K. PY - 2004 DA - 2004// TI - Tyrosine kinase–role and significance in cancer JO - Int J Med Sci VL - 1 UR - https://doi.org/10.7150/ijms.1.101 DO - 10.7150/ijms.1.101 ID - Paul2004 ER - TY - JOUR AU - Grassot, J. AU - Mouchiroud, G. AU - Perrière, G. PY - 2003 DA - 2003// TI - RTKdb: database of receptor tyrosine kinase JO - Nucleic Acids Res VL - 31 UR - https://doi.org/10.1093/nar/gkg036 DO - 10.1093/nar/gkg036 ID - Grassot2003 ER - TY - JOUR AU - Ullrich, A. AU - Schlessinger, J. PY - 1990 DA - 1990// TI - Signal transduction by receptors with tyrosine kinase activity JO - Cell VL - 61 UR - https://doi.org/10.1016/0092-8674(90)90801-K DO - 10.1016/0092-8674(90)90801-K ID - Ullrich1990 ER - TY - JOUR AU - Ocana, A. AU - Serrano, R. AU - Calero, R. AU - Pandiella, A. PY - 2009 DA - 2009// TI - Novel tyrosine kinase inhibitors in the treatment of cancer JO - Curr Drug Targets VL - 10 UR - https://doi.org/10.2174/138945009788488378 DO - 10.2174/138945009788488378 ID - Ocana2009 ER - TY - JOUR AU - Hubbard, S. R. PY - 1997 DA - 1997// TI - Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog JO - EMBO J VL - 16 UR - https://doi.org/10.1093/emboj/16.18.5572 DO - 10.1093/emboj/16.18.5572 ID - Hubbard1997 ER - TY - JOUR AU - Paul, M. K. AU - Mukhopadhyay, A. K. PY - 2004 DA - 2004// TI - Tyrosine kinase–role and significance in cancer JO - Int J Med Sci VL - 1 UR - https://doi.org/10.7150/ijms.1.101 DO - 10.7150/ijms.1.101 ID - Paul2004 ER - TY - JOUR AU - Lemmon, M. A. AU - Schlessinger, J. PY - 2010 DA - 2010// TI - Cell signaling by receptor tyrosine kinases JO - Cell VL - 141 UR - https://doi.org/10.1016/j.cell.2010.06.011 DO - 10.1016/j.cell.2010.06.011 ID - Lemmon2010 ER - TY - JOUR AU - Blume-Jensen, P. AU - Hunter, T. PY - 2001 DA - 2001// TI - Oncogenic kinase signalling JO - Nature VL - 411 UR - https://doi.org/10.1038/35077225 DO - 10.1038/35077225 ID - Blume-Jensen2001 ER - TY - JOUR AU - Cohen, P. PY - 2002 DA - 2002// TI - Protein kinases—the major drug targets of the twenty-first century? JO - Nat Rev Drug Discov VL - 1 UR - https://doi.org/10.1038/nrd773 DO - 10.1038/nrd773 ID - Cohen2002 ER - TY - JOUR AU - Ushiro, H. AU - Cohen, S. PY - 1980 DA - 1980// TI - Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes JO - J Biol Chem VL - 255 ID - Ushiro1980 ER - TY - JOUR AU - Kasuga, M. AU - Zick, Y. AU - Blithe, D. L. AU - Crettaz, M. AU - Kahn, C. R. PY - 1982 DA - 1982// TI - Insulin stimulates tyrosine phosphorylation of the insulin receptor in a cell-free system JO - Nature VL - 298 UR - https://doi.org/10.1038/298667a0 DO - 10.1038/298667a0 ID - Kasuga1982 ER - TY - JOUR AU - Hubbard, S. R. PY - 1999 DA - 1999// TI - Structural analysis of receptor tyrosine kinases JO - Prog Biophys Mol Biol VL - 71 UR - https://doi.org/10.1016/s0079-6107(98)00047-9 DO - 10.1016/s0079-6107(98)00047-9 ID - Hubbard1999 ER - TY - JOUR AU - Vogelstein, B. AU - Papadopoulos, N. AU - Velculescu, V. E. AU - Zhou, S. AU - Diaz, L. A. AU - Kinzler, K. W. PY - 2013 DA - 2013// TI - Cancer genome landscapes JO - Science VL - 339 UR - https://doi.org/10.1126/science.1235122 DO - 10.1126/science.1235122 ID - Vogelstein2013 ER - TY - JOUR AU - Bennasroune, A. AU - Gardin, A. AU - Aunis, D. AU - Crémel, G. AU - Hubert, P. PY - 2004 DA - 2004// TI - Tyrosine kinase receptors as attractive targets of cancer therapy JO - Crit Rev Oncol Hematol VL - 50 UR - https://doi.org/10.1016/j.critrevonc.2003.08.004 DO - 10.1016/j.critrevonc.2003.08.004 ID - Bennasroune2004 ER - TY - JOUR AU - Li, E. AU - Hristova, K. PY - 2010 DA - 2010// TI - Receptor tyrosine kinase transmembrane domains: function, dimer structure and dimerization energetics JO - Cell Adhes Migr VL - 4 UR - https://doi.org/10.4161/cam.4.2.10725 DO - 10.4161/cam.4.2.10725 ID - Li2010 ER - TY - JOUR AU - Hao, D. AU - Rowinsky, E. K. PY - 2002 DA - 2002// TI - Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors JO - Cancer Investig VL - 20 UR - https://doi.org/10.1081/CNV-120001184 DO - 10.1081/CNV-120001184 ID - Hao2002 ER - TY - JOUR AU - Holland, S. J. AU - Peles, E. AU - Pawson, T. AU - Schlessinger, J. PY - 1998 DA - 1998// TI - Cell-contact-dependent signalling in axon growth and guidance: Eph receptor tyrosine kinases and receptor protein tyrosine phosphatase β JO - Curr Opin Neurobiol VL - 8 UR - https://doi.org/10.1016/S0959-4388(98)80015-9 DO - 10.1016/S0959-4388(98)80015-9 ID - Holland1998 ER - TY - JOUR AU - Mannig, G. AU - Whyte, D. B. AU - Martinez, R. AU - Hunter, T. AU - Sudarsanam, S. PY - 2002 DA - 2002// TI - The protein kinase complement of the human genome JO - Science VL - 298 UR - https://doi.org/10.1126/science.1075762 DO - 10.1126/science.1075762 ID - Mannig2002 ER - TY - JOUR AU - Noble, M. AU - Endicott, J. A. AU - Johnson, L. N. PY - 2004 DA - 2004// TI - Protein kinase inhibitors: insights into drug design from structure JO - Science VL - 303 UR - https://doi.org/10.1126/science.1095920 DO - 10.1126/science.1095920 ID - Noble2004 ER - TY - JOUR AU - Liu, Y. AU - Shah, K. AU - Yang, F. AU - Witucki, L. AU - Shokat, K. M. PY - 1998 DA - 1998// TI - A molecular gate, which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src JO - Bioorg Med Chem VL - 6 UR - https://doi.org/10.1016/S0968-0896(98)00099-6 DO - 10.1016/S0968-0896(98)00099-6 ID - Liu1998 ER - TY - JOUR AU - Huse, M. AU - Kuriyan, J. PY - 2002 DA - 2002// TI - The conformational plasticity of protein kinases JO - Cell VL - 109 UR - https://doi.org/10.1016/S0092-8674(02)00741-9 DO - 10.1016/S0092-8674(02)00741-9 ID - Huse2002 ER - TY - JOUR AU - Nagar, B. PY - 2007 DA - 2007// TI - C-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI571) JO - J Nutr VL - 137 UR - https://doi.org/10.1093/jn/137.6.1518S DO - 10.1093/jn/137.6.1518S ID - Nagar2007 ER - TY - JOUR AU - Sicheri, F. AU - Moarefi, I. AU - Kuriyan, J. PY - 1997 DA - 1997// TI - Crystal structure of the Src family tyrosine kinase Hck JO - Nature VL - 385 UR - https://doi.org/10.1038/385602a0 DO - 10.1038/385602a0 ID - Sicheri1997 ER - TY - JOUR AU - Peng, Y. H. AU - Shiao, H. Y. AU - Tu, C. H. AU - Liu, P. M. AU - Hsu, J. T. A. AU - Amancha, P. K. PY - 2013 DA - 2013// TI - Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors JO - J Med Chem VL - 56 UR - https://doi.org/10.1021/jm400072p DO - 10.1021/jm400072p ID - Peng2013 ER - TY - JOUR AU - Robinson, D. R. AU - Wu, Y. M. AU - Lin, S. F. PY - 2000 DA - 2000// TI - The protein tyrosine kinase family of the human genome JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1203957 DO - 10.1038/sj.onc.1203957 ID - Robinson2000 ER - TY - JOUR AU - Schlessinger, J. PY - 2000 DA - 2000// TI - Cell signaling by receptor tyrosine kinases JO - Cell VL - 103 UR - https://doi.org/10.1016/S0092-8674(00)00114-8 DO - 10.1016/S0092-8674(00)00114-8 ID - Schlessinger2000 ER - TY - STD TI - Rosell R, Karachaliou N (2019) Co-mutations in EGFR driven non-small cell lung cancer. EBioMedicine. https://doi.org/10.1016/j.ebiom.2019.03.03 ID - ref28 ER - TY - JOUR AU - Jiang, J. AU - Protopopov, A. AU - Sun, R. AU - Lyle, S. AU - Russell, M. PY - 2018 DA - 2018// TI - Genomic profiling on an unselected solid tumor population reveals a highly mutated Wnt/β-catenin pathway associated with oncogenic EGFR mutations JO - J Pers Med VL - 8 UR - https://doi.org/10.3390/jpm802001 DO - 10.3390/jpm802001 ID - Jiang2018 ER - TY - JOUR AU - Mitsudomi, T. AU - Yatabe, Y. PY - 2010 DA - 2010// TI - Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer JO - FEBS J VL - 277 UR - https://doi.org/10.1111/j.1742-4658.2009.07448.x DO - 10.1111/j.1742-4658.2009.07448.x ID - Mitsudomi2010 ER - TY - JOUR AU - Dziadziuszko, R. AU - Jassem, J. PY - 2012 DA - 2012// TI - Epidermal growth factor receptor (EGFR) inhibitors and derived treatments JO - Ann Oncol VL - 23 UR - https://doi.org/10.1093/annonc/mds35 DO - 10.1093/annonc/mds35 ID - Dziadziuszko2012 ER - TY - JOUR AU - Ramalingam, S. AU - Yang, J. C. H. AU - Lee, C. K. AU - Kurata, T. AU - Kim, D. W. AU - John, T. AU - Nogami, N. AU - Ohe, Y. AU - Janne, P. A. PY - 2016 DA - 2016// TI - Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two phase I expansion cohorts JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/S1556-0864(16)30324-0 DO - 10.1016/S1556-0864(16)30324-0 ID - Ramalingam2016 ER - TY - JOUR AU - Jänne, P. A. AU - Yang, J. C. AU - Kim, D. W. AU - Planchard, D. AU - Ohe, Y. AU - Ramalingam, S. S. AU - Ahn, M. J. AU - Kim, S. W. AU - Su, W. C. AU - Horn, L. AU - Haggstrom, D. AU - Felip, E. AU - Kim, J. H. AU - Frewer, P. AU - Cantarini, M. AU - Brown, K. H. AU - Dickinson, P. A. AU - Ghiorghiu, S. AU - Ranson, M. PY - 2015 DA - 2015// TI - AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1411817 DO - 10.1056/NEJMoa1411817 ID - Jänne2015 ER - TY - JOUR AU - Wang, S. AU - Cang, S. AU - Liu, D. PY - 2016 DA - 2016// TI - Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer JO - Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0268-z DO - 10.1186/s13045-016-0268-z ID - Wang2016 ER - TY - JOUR AU - Liao, B. C. AU - Lin, C. C. AU - Lee, J. H. AU - Yang, J. C. PY - 2016 DA - 2016// TI - Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptortyrosine kinase inhibitors JO - J Biomed Sci VL - 23 UR - https://doi.org/10.1186/s12929-016-0305-9 DO - 10.1186/s12929-016-0305-9 ID - Liao2016 ER - TY - BOOK PY - 2017 DA - 2017// TI - Breast cancer facts & figures 2017–2018 PB - American Cancer Society, Inc. CY - Atlanta ID - ref36 ER - TY - JOUR AU - Wee, P. AU - Wang, Z. PY - 2017 DA - 2017// TI - Epidermal growth factor receptor cell proliferation signaling pathways JO - Cancers VL - 9 UR - https://doi.org/10.3390/cancers9050052 DO - 10.3390/cancers9050052 ID - Wee2017 ER - TY - JOUR AU - Ferrara, N. AU - Kerbel, R. S. PY - 2005 DA - 2005// TI - Angiogenesis as a therapeutic target JO - Nature VL - 438 UR - https://doi.org/10.1038/nature04483 DO - 10.1038/nature04483 ID - Ferrara2005 ER - TY - JOUR AU - Alitalo, K. AU - Carmeliet, P. PY - 2002 DA - 2002// TI - Molecular mechanisms of lymphangiogenesis in health and disease JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00051-X DO - 10.1016/S1535-6108(02)00051-X ID - Alitalo2002 ER - TY - JOUR AU - Shibuya, M. PY - 2011 DA - 2011// TI - Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies JO - Genes Cancer VL - 2 UR - https://doi.org/10.1177/1947601911423031 DO - 10.1177/1947601911423031 ID - Shibuya2011 ER - TY - JOUR AU - Iacovelli, R. AU - Sternberg, C. N. AU - Porta, C. AU - Verzoni, E. AU - Braud, F. AU - Escudier, B. AU - Procopio, G. PY - 2015 DA - 2015// TI - Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis JO - Curr Drug Targets VL - 16 UR - https://doi.org/10.2174/1389450115666141120120145 DO - 10.2174/1389450115666141120120145 ID - Iacovelli2015 ER - TY - JOUR AU - Chen, P. H. AU - Chen, X. AU - He, X. PY - 2013 DA - 2013// TI - Platelet-derived growth factors and their receptors: structural and functional perspectives JO - Biochim Biophys Acta VL - 1834 UR - https://doi.org/10.1016/j.bbapap.2012.10.015 DO - 10.1016/j.bbapap.2012.10.015 ID - Chen2013 ER - TY - JOUR AU - Cao, Y. PY - 2013 DA - 2013// TI - Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis JO - Trends Mol Med VL - 19 UR - https://doi.org/10.1016/j.molmed.2013.05.002 DO - 10.1016/j.molmed.2013.05.002 ID - Cao2013 ER - TY - JOUR AU - Koschmann, C. AU - Zamler, D. AU - MacKay, A. AU - Robinson, D. AU - Wu, Y. M. AU - Doherty, R. AU - Marini, B. AU - Tran, D. AU - Garton, H. AU - Muraszko, K. PY - 2016 DA - 2016// TI - Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.11602 DO - 10.18632/oncotarget.11602 ID - Koschmann2016 ER - TY - JOUR AU - Dong, J. AU - Grunstein, J. AU - Tejada, M. AU - Peale, F. AU - Frantz, G. AU - Liang, W. C. PY - 2004 DA - 2004// TI - VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis JO - EMBO J VL - 23 UR - https://doi.org/10.1038/sj.emboj.7600289 DO - 10.1038/sj.emboj.7600289 ID - Dong2004 ER - TY - JOUR AU - Gotzmann, J. AU - Fischer, A. N. M. AU - Zojer, M. AU - Mikula, M. AU - Proell, V. AU - Huber, H. PY - 2006 DA - 2006// TI - A crucial function of PDGF in TGF-β-mediated cancer progression of hepatocytes JO - Oncogene VL - 25 UR - https://doi.org/10.1038/sj.onc.1209083 DO - 10.1038/sj.onc.1209083 ID - Gotzmann2006 ER - TY - JOUR AU - Wu, E. AU - Palmer, N. AU - Tian, Z. AU - Moseman, A. P. AU - Galdzicki, M. AU - Wang, X. PY - 2008 DA - 2008// TI - Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells JO - PLoS One VL - 3 UR - https://doi.org/10.1371/journal.pone.0003794 DO - 10.1371/journal.pone.0003794 ID - Wu2008 ER - TY - JOUR AU - Duckett, D. R. AU - Cameron, M. D. PY - 2010 DA - 2010// TI - Metabolism considerations for kinase inhibitors in cancer treatment JO - Expert Opin Drug Metab Toxicol VL - 6 UR - https://doi.org/10.1517/17425255.2010.506873 DO - 10.1517/17425255.2010.506873 ID - Duckett2010 ER - TY - JOUR AU - Taniguchi, C. M. AU - Emanuelli, B. AU - Kahn, C. R. PY - 2006 DA - 2006// TI - Critical nodes in signaling pathways: insights into insulin action JO - Nat Rev Mol Cell Biol VL - 7 UR - https://doi.org/10.1038/nrm1837 DO - 10.1038/nrm1837 ID - Taniguchi2006 ER - TY - JOUR AU - Ward, C. W. AU - Lawrence, M. C. PY - 2009 DA - 2009// TI - Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor JO - BioEssays VL - 31 UR - https://doi.org/10.1002/bies.200800210 DO - 10.1002/bies.200800210 ID - Ward2009 ER - TY - JOUR AU - White, M. F. PY - 1998 DA - 1998// TI - The IRS-signaling system: a network of docking proteins that mediate insulin action JO - Mol Cell Biochem VL - 82 UR - https://doi.org/10.1023/A:1006806722619 DO - 10.1023/A:1006806722619 ID - White1998 ER - TY - JOUR AU - Papa, V. AU - Pezzino, V. AU - Costantino, A. AU - Belfiore, A. AU - Giuffrida, D. AU - Frittitta, L. PY - 1990 DA - 1990// TI - Elevated insulin receptor content in human breast cancer JO - J Clin Invest VL - 86 UR - https://doi.org/10.1172/JCI114868 DO - 10.1172/JCI114868 ID - Papa1990 ER - TY - STD TI - Malaguarnera R, Belfiore A (2011) The insulin receptor: a new target for cancer therapy. Front Endocrinol 2. https://doi.org/10.3389/fendo.2011.00093 ID - ref53 ER - TY - STD TI - Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer 17(1). https://doi.org/10.1186/s12943-018-0804-2 ID - ref54 ER - TY - JOUR AU - Dar, A. r. v. i. n. C. AU - Shokat, K. e. v. a. n. M. PY - 2011 DA - 2011// TI - The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling JO - Annual Review of Biochemistry VL - 80 UR - https://doi.org/10.1146/annurev-biochem-090308-173656 DO - 10.1146/annurev-biochem-090308-173656 ID - Dar2011 ER - TY - JOUR AU - Zuccotto, F. AU - Ardini, E. AU - Casale, E. AU - Angiolini, M. PY - 2009 DA - 2009// TI - Through the “gatekeeper door”: exploiting the active kinase conformation JO - J Med Chem VL - 53 UR - https://doi.org/10.1021/jm901443h DO - 10.1021/jm901443h ID - Zuccotto2009 ER - TY - JOUR AU - Gavrin, L. K. AU - Saiah, E. PY - 2013 DA - 2013// TI - Approaches to discover non-ATP site kinase inhibitors JO - MedChemComm VL - 4 UR - https://doi.org/10.1039/C2MD20180A DO - 10.1039/C2MD20180A ID - Gavrin2013 ER - TY - JOUR AU - Lamba, V. AU - Ghosh, I. PY - 2012 DA - 2012// TI - New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors JO - Curr Pharm Des VL - 18 UR - https://doi.org/10.2174/138161212800672813 DO - 10.2174/138161212800672813 ID - Lamba2012 ER - TY - JOUR AU - Zhang, J. AU - Yang, P. L. AU - Gray, N. S. PY - 2009 DA - 2009// TI - Targeting cancer with small molecule kinase inhibitors JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2559 DO - 10.1038/nrc2559 ID - Zhang2009 ER - TY - JOUR AU - Davis, M. I. AU - Hunt, J. P. AU - Herrgard, S. AU - Ciceri, P. AU - Wodicka, L. M. AU - Pallares, G. AU - Hocker, M. AU - Treiber, D. K. AU - Zarrinkar, P. P. PY - 2011 DA - 2011// TI - Comprehensive analysis of kinase inhibitor selectivity JO - Nat Biotechnol VL - 29 UR - https://doi.org/10.1038/nbt.1990 DO - 10.1038/nbt.1990 ID - Davis2011 ER - TY - JOUR AU - Ni, J. u. n. AU - Zhang, L. i. PY - 2016 DA - 2016// TI - Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer JO - Chinese Medical Journal VL - 129 UR - https://doi.org/10.4103/0366-6999.174484 DO - 10.4103/0366-6999.174484 ID - Ni2016 ER - TY - JOUR AU - Roskoski, R. PY - 2016 DA - 2016// TI - Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes JO - Pharmacol Res VL - 103 UR - https://doi.org/10.1016/j.phrs.2015.10.021 DO - 10.1016/j.phrs.2015.10.021 ID - Roskoski2016 ER - TY - JOUR AU - Jabbour, E. AU - Kantarjian, H. AU - Cortes, J. PY - 2015 DA - 2015// TI - Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm JO - Clin Lymphoma Myeloma Leuk VL - 15 UR - https://doi.org/10.1016/j.clml.2015.03.006 DO - 10.1016/j.clml.2015.03.006 ID - Jabbour2015 ER - TY - JOUR AU - Tokarski, J. S. AU - Newitt, J. A. AU - Chang, C. Y. J. AU - Cheng, J. D. AU - Wittekind, M. AU - Kiefer, S. E. PY - 2006 DA - 2006// TI - The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against Imatinib-resistant ABL mutants JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.can-05-4187 DO - 10.1158/0008-5472.can-05-4187 ID - Tokarski2006 ER - TY - JOUR AU - Rothenstein, J. M. AU - Chooback, N. PY - 2018 DA - 2018// TI - ALK inhibitors, resistance development, clinical trials JO - Curr Oncol VL - 25 UR - https://doi.org/10.3747/co.25.3760 DO - 10.3747/co.25.3760 ID - Rothenstein2018 ER - TY - JOUR AU - Hasinoff, B. B. PY - 2010 DA - 2010// TI - The cardiotoxicity and myocyte damage caused by small molecule anticancer tyrosine kinase inhibitors is correlated with lack of target specificity JO - Toxicol Appl Pharmacol VL - 244 UR - https://doi.org/10.1016/j.taap.2009.12.032 DO - 10.1016/j.taap.2009.12.032 ID - Hasinoff2010 ER - TY - JOUR AU - Chaar, M. AU - Kamta, J. AU - Ait-Oudhia, S. PY - 2018 DA - 2018// TI - Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities JO - OncoTargets Ther VL - 11 UR - https://doi.org/10.2147/OTT.S170138 DO - 10.2147/OTT.S170138 ID - Chaar2018 ER - TY - JOUR AU - Kufareva, I. AU - Abagyan, R. PY - 2008 DA - 2008// TI - Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states JO - J Med Chem VL - 51 UR - https://doi.org/10.1021/jm8010299 DO - 10.1021/jm8010299 ID - Kufareva2008 ER - TY - JOUR AU - Bhullar, K. S. AU - Lagarón, N. O. AU - McGowan, E. M. AU - Parmar, I. AU - Jha, A. AU - Hubbard, B. P. AU - Rupasinghe, H. PY - 2018 DA - 2018// TI - Kinase-targeted cancer therapies: progress, challenges and future directions JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0804-2 DO - 10.1186/s12943-018-0804-2 ID - Bhullar2018 ER - TY - JOUR AU - Henkes, M. AU - Kuip, H. AU - Aulitzky, W. E. PY - 2008 DA - 2008// TI - Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, GleevecTM) JO - Ther Clin Risk Manag VL - 4 ID - Henkes2008 ER - TY - JOUR AU - Mugha, T. I. AU - Schrieber, A. PY - 2010 DA - 2010// TI - Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia JO - Biol Targets Ther VL - 4 UR - https://doi.org/10.2147/BTT.S5775 DO - 10.2147/BTT.S5775 ID - Mugha2010 ER - TY - JOUR AU - Ran, H. H. AU - Zhang, R. AU - Lu, X. C. AU - Yang, B. AU - Fan, H. AU - Zhu, H. L. PY - 2012 DA - 2012// TI - Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review JO - J Geriatr Cardiol VL - 9 UR - https://doi.org/10.3724/SP.J.1263.2012.05251 DO - 10.3724/SP.J.1263.2012.05251 ID - Ran2012 ER - TY - JOUR AU - Pye, S. M. AU - Cortes, J. AU - Ault, P. AU - Hatfield, A. AU - Kantarjian, H. AU - Pilot, R. PY - 2008 DA - 2008// TI - The effects of imatinib on pregnancy outcome JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-10-114900 DO - 10.1182/blood-2007-10-114900 ID - Pye2008 ER - TY - JOUR AU - Ross, D. M. AU - Branford, S. AU - Seymour, J. F. AU - Schwarer, A. P. AU - Arthur, C. AU - Yeung, D. T. PY - 2013 DA - 2013// TI - Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study JO - Blood VL - 122 UR - https://doi.org/10.1182/blood-2013-02-483750 DO - 10.1182/blood-2013-02-483750 ID - Ross2013 ER - TY - JOUR AU - Scott, L. C. AU - White, J. D. AU - Reid, R. AU - Cowie, F. PY - 2005 DA - 2005// TI - Management of skin toxicity related to the use of Imatinib Mesylate (STI571, Glivectrade mark) for advanced stage gastrointestinal stromal Tumours JO - Sarcoma VL - 9 UR - https://doi.org/10.1080/13577140500349717 DO - 10.1080/13577140500349717 ID - Scott2005 ER - TY - JOUR AU - Gambacorti-Passerini, C. AU - Tornaghi, L. AU - Cavagnini, F. AU - Rossi, P. AU - Pecori-Giraldi, F. AU - Mariani, L. PY - 2003 DA - 2003// TI - Gynaecomastia in men with chronic myeloid leukaemia after imatinib JO - Lancet VL - 361 UR - https://doi.org/10.1016/s0140-6736(03)13554-4 DO - 10.1016/s0140-6736(03)13554-4 ID - Gambacorti-Passerini2003 ER - TY - JOUR AU - Tanriverdi, O. AU - Unubol, M. AU - Taskin, F. AU - Meydan, N. AU - Sargin, G. AU - Guney, E. AU - Barutca, S. PY - 2011 DA - 2011// TI - Imatinib-associated bilateral gynecomastia and unilateral testicular hydrocele in male patient with metastatic gastrointestinal stromal tumor: a literature review JO - J Oncol Pharm Pract VL - 18 UR - https://doi.org/10.1177/107815521142462 DO - 10.1177/107815521142462 ID - Tanriverdi2011 ER - TY - JOUR AU - Tavil, B. AU - Kınık, S. AU - Gözen, A. AU - Olcay, L. PY - 2013 DA - 2013// TI - Gynecomastia in a boy with chronic myeloid leukemia during Imatinib therapy JO - Turk J Haematol VL - 30 UR - https://doi.org/10.4274/TJH-2013-0109 DO - 10.4274/TJH-2013-0109 ID - Tavil2013 ER - TY - JOUR AU - Santachiara, R. AU - Maffei, R. AU - Martinelli, S. AU - Arcari, A. AU - Piacentini, F. AU - Trabacchi, E. AU - Alfieri, P. AU - Ferrari, A. AU - Leonardi, G. AU - Luppi, G. AU - Longo, G. AU - Vallisa, D. AU - Marasca, R. AU - Torelli, G. PY - 2008 DA - 2008// TI - Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia and gastrointestinal stromal tumor JO - Haematologica VL - 93 UR - https://doi.org/10.3324/haematol.12642 DO - 10.3324/haematol.12642 ID - Santachiara2008 ER - TY - JOUR AU - Seliger, B. AU - Massa, C. AU - Rini, B. AU - Ko, J. AU - Finke, J. PY - 2010 DA - 2010// TI - Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors JO - Trends Mol Med VL - 16 UR - https://doi.org/10.1016/j.molmed.2010.02.001 DO - 10.1016/j.molmed.2010.02.001 ID - Seliger2010 ER - TY - JOUR AU - Talpaz, M. PY - 2002 DA - 2002// TI - Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study JO - Blood VL - 99 UR - https://doi.org/10.1182/blood.v99.6.1928 DO - 10.1182/blood.v99.6.1928 ID - Talpaz2002 ER - TY - JOUR AU - Haq, M. I. AU - Nixon, J. AU - Stanley, A. J. PY - 2018 DA - 2018// TI - Imatinib and liver toxicity JO - BMJ Case Rep VL - 11 UR - https://doi.org/10.1136/bcr-2018-226740 DO - 10.1136/bcr-2018-226740 ID - Haq2018 ER - TY - JOUR AU - Jabbour, E. AU - Kantarjian, H. M. AU - Abruzzo, L. V. AU - O’Brien, S. AU - Garcia-Manero, G. AU - Verstovsek, S. PY - 2007 DA - 2007// TI - Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-01-07004 DO - 10.1182/blood-2007-01-07004 ID - Jabbour2007 ER - TY - STD TI - Sheeba CJ, Marslin G, Revina AM, Khandelwal V, Balakumar K, Prakash J, Franklin G (2015) Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity. Int J Nanomed 3163. https://doi.org/10.2147/ijn.s75962 ID - ref84 ER - TY - JOUR AU - Pitoia, F. AU - Jerkovich, F. PY - 2016 DA - 2016// TI - Selective use of sorafenib in the treatment of thyroid cancer JO - Drug Des Devel Ther VL - 10 UR - https://doi.org/10.2147/DDDT.S82972 DO - 10.2147/DDDT.S82972 ID - Pitoia2016 ER - TY - JOUR AU - Xie, B. AU - Wang, D. H. AU - Spechler, S. J. PY - 2012 DA - 2012// TI - Sorafenib for treatment of hepatocellular carcinoma: a systematic review JO - Dig Dis Sci VL - 57 UR - https://doi.org/10.1007/s10620-012-2136-1 DO - 10.1007/s10620-012-2136-1 ID - Xie2012 ER - TY - JOUR AU - Brose, M. S. AU - Frenette, C. T. AU - Keefe, S. M. AU - Stein, S. M. PY - 2014 DA - 2014// TI - Management of sorafenib-related adverse events: a clinician’s perspective JO - Semin Oncol VL - 41 UR - https://doi.org/10.1053/j.seminoncol.2014.01.00 DO - 10.1053/j.seminoncol.2014.01.00 ID - Brose2014 ER - TY - JOUR AU - Weisberg, E. AU - Manley, P. W. AU - Breitenstein, W. AU - Brüggen, J. AU - Cowan-Jacob, S. W. AU - Ray, A. PY - 2005 DA - 2005// TI - Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl JO - Cancer Cell VL - 7 UR - https://doi.org/10.1016/j.ccr.2005.01.007 DO - 10.1016/j.ccr.2005.01.007 ID - Weisberg2005 ER - TY - STD TI - Center for Drug Evaluation and Research (2007) Nilotinib pharmacology/toxicology review and evaluation ID - ref89 ER - TY - JOUR AU - Goldenberg, M. M. PY - 2008 DA - 2008// TI - Pharmaceutical approval update JO - P & T Peer Rev J Formul Manag VL - 33 ID - Goldenberg2008 ER - TY - JOUR AU - Bellesoeur, A. u. d. r. e. y. AU - Carton, E. d. i. t. h. AU - Alexandre, J. e. r. o. m. e. AU - Goldwasser, F. r. a. n. c. o. i. s. AU - Huillard, O. l. i. v. i. e. r. PY - 2017 DA - 2017// TI - Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy JO - Drug Design, Development and Therapy VL - Volume 11 UR - https://doi.org/10.2147/DDDT.S109640 DO - 10.2147/DDDT.S109640 ID - Bellesoeur2017 ER - TY - JOUR AU - Cohen, E. E. AU - Rosen, L. S. AU - Vokes, E. E. AU - Kies, M. S. AU - Forastiere, A. A. AU - Worden, F. P. AU - Kane, M. A. AU - Sherman, E. AU - Kim, S. AU - Bycott, P. AU - Tortorici, M. AU - Shalinsky, D. R. AU - Liau, K. F. AU - Cohen, R. B. PY - 2008 DA - 2008// TI - Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.9566 DO - 10.1200/JCO.2007.15.9566 ID - Cohen2008 ER - TY - JOUR AU - Schiller, J. H. AU - Larson, T. AU - Ou, S. -. H. I. AU - Limentani, S. AU - Sandler, A. AU - Vokes, E. PY - 2009 DA - 2009// TI - Efficacy and safety of Axitinib in patients with advanced non–small-cell lung Cancer: results from a phase II study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/jco.2008.20.8355 DO - 10.1200/jco.2008.20.8355 ID - Schiller2009 ER - TY - JOUR AU - Gunnarsson, O. AU - Pfanzelter, N. R. AU - Cohen, R. B. AU - Keefe, S. M. PY - 2015 DA - 2015// TI - Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma JO - Cancer Manag Res VL - 7 UR - https://doi.org/10.2147/CMAR.S74202 DO - 10.2147/CMAR.S74202 ID - Gunnarsson2015 ER - TY - CHAP AU - Amato, R. o. b. e. r. t. J. AU - Stepankiw, M. i. k. a. AU - Ochuwa, N. w. a. b. u. g. w. u. S. PY - 2014 DA - 2014// TI - Molecular-targeted Therapy for Renal Cell Carcinoma BT - Renal Disease in Cancer Patients UR - https://doi.org/10.1016/B978-0-12-415948-8.00008-8 DO - 10.1016/B978-0-12-415948-8.00008-8 ID - Amato2014 ER - TY - JOUR AU - Fasano, M. AU - Della Corte, C. M. AU - Califano, R. AU - Capuano, A. AU - Troiani, T. AU - Martinelli, E. PY - 2014 DA - 2014// TI - Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer JO - Expert Opin Investig Drugs VL - 23 UR - https://doi.org/10.1517/13543784.2014.902934 DO - 10.1517/13543784.2014.902934 ID - Fasano2014 ER - TY - JOUR AU - Morrow, J. K. AU - Du-Cuny, L. AU - Chen, L. AU - Meuillet, E. J. AU - Mash, E. A. AU - Powis, G. AU - Zhang, S. PY - 2011 DA - 2011// TI - Recent development of anticancer therapeutics targeting Akt JO - Recent Pat Anticancer Drug Discov VL - 6 UR - https://doi.org/10.2174/157489211793980079 DO - 10.2174/157489211793980079 ID - Morrow2011 ER - TY - JOUR AU - Papadimitrakopoulou, V. PY - 2012 DA - 2012// TI - Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non–small-cell lung Cancer JO - J Thorac Oncol VL - 7 UR - https://doi.org/10.1097/jto.0b013e31825493e DO - 10.1097/jto.0b013e31825493e ID - Papadimitrakopoulou2012 ER - TY - JOUR AU - Gumireddy, K. AU - Baker, S. J. AU - Cosenza, S. C. AU - John, P. AU - Kang, A. D. AU - Robell, K. A. PY - 2005 DA - 2005// TI - A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance JO - Proc Natl Acad Sci U S A VL - 102 UR - https://doi.org/10.1073/pnas.0408283102 DO - 10.1073/pnas.0408283102 ID - Gumireddy2005 ER - TY - JOUR AU - Zhao, Z. AU - Liu, Q. AU - Bliven, S. AU - Xie, L. AU - Bourne, P. E. PY - 2017 DA - 2017// TI - Determining cysteines available for covalent inhibition across the human Kinome JO - J Med Chem VL - 60 UR - https://doi.org/10.1021/acs.jmedchem.6b01815 DO - 10.1021/acs.jmedchem.6b01815 ID - Zhao2017 ER - TY - JOUR AU - Liu, Q. AU - Sabnis, Y. AU - Zhao, Z. AU - Zhang, T. AU - Buhrlage, S. J. AU - Jones, L. H. AU - Gray, N. S. PY - 2013 DA - 2013// TI - Developing irreversible inhibitors of the protein kinase cysteinome JO - Chem Biol VL - 20 UR - https://doi.org/10.1016/j.chembiol.2012.12.006 DO - 10.1016/j.chembiol.2012.12.006 ID - Liu2013 ER - TY - JOUR AU - Barf, T. AU - Kaptein, A. PY - 2012 DA - 2012// TI - Irreversible protein kinase inhibitors: balancing the benefits and risks JO - J Med Chem VL - 55 UR - https://doi.org/10.1021/jm3003203 DO - 10.1021/jm3003203 ID - Barf2012 ER - TY - JOUR AU - Cross, D. A. AU - Ashton, S. E. AU - Ghiorghiu, S. AU - Eberlein, C. AU - Nebhan, C. A. AU - Spitzler, P. J. AU - Orme, J. P. AU - Finlay, M. R. AU - Ward, R. A. AU - Mellor, M. J. AU - Hughes, G. AU - Rahi, A. AU - Jacobs, V. N. AU - Brewer, R. M. AU - Ichihara, E. AU - Sun, J. AU - Jin, H. AU - Ballard, P. AU - Al-Kadhimi, K. AU - Rowlinson, R. AU - Klinowska, T. AU - Richmond, G. H. AU - Cantarini, M. AU - Kim, D. W. AU - Ranson, M. R. AU - Pao, W. PY - 2014 DA - 2014// TI - Azd9291, an irreversible egfr tki, overcomes t790m-mediated resistance to egfr inhibitors in lung cancer JO - Cancer Dis VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0337 DO - 10.1158/2159-8290.CD-14-0337 ID - Cross2014 ER - TY - JOUR AU - Jiang, T. AU - Su, C. AU - Ren, S. AU - Cappuzzo, F. AU - Rocco, G. AU - Palmer, J. D. PY - 2018 DA - 2018// TI - A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group JO - J Thorac Dis VL - 10 UR - https://doi.org/10.21037/jtd.2018.07.61 DO - 10.21037/jtd.2018.07.61 ID - Jiang2018 ER - TY - JOUR AU - Klohs, W. D. AU - Fry, D. W. AU - Kraker, A. J. PY - 1997 DA - 1997// TI - Inhibitors of tyrosine kinase JO - Curr Opin Oncol VL - 9 UR - https://doi.org/10.1097/00001622-199711000-00012 DO - 10.1097/00001622-199711000-00012 ID - Klohs1997 ER - TY - JOUR AU - Peterson, G. AU - Barnes, S. PY - 1996 DA - 1996// TI - Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells JO - Cell Growth Differ VL - 10 ID - Peterson1996 ER - TY - JOUR AU - Ferrara, N. PY - 2002 DA - 2002// TI - Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications JO - Semin Oncol VL - 29 UR - https://doi.org/10.1053/sonc.2002.37264 DO - 10.1053/sonc.2002.37264 ID - Ferrara2002 ER - TY - JOUR AU - McCarthy, M. PY - 2003 DA - 2003// TI - Antiangiogenesis drug promising for metastatic Colo- rectal cancer JO - Lancet VL - 361 UR - https://doi.org/10.1016/S0140-6736(03)13603-3 DO - 10.1016/S0140-6736(03)13603-3 ID - McCarthy2003 ER - TY - JOUR AU - Nishida, N. AU - Yano, H. AU - Nishida, T. AU - Kamura, T. AU - Kojiro, M. PY - 2003 DA - 2003// TI - Angiogenesis in cancer JO - Vasc Health Risk Manag VL - 2 UR - https://doi.org/10.2147/vhrm.2006.2.3.213 DO - 10.2147/vhrm.2006.2.3.213 ID - Nishida2003 ER - TY - JOUR AU - Kim, K. J. AU - Li, B. AU - Winer, J. AU - Armanini, M. AU - Gillett, N. AU - Phillips, H. S. AU - Ferrara, N. PY - 1993 DA - 1993// TI - Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo JO - Nature VL - 362 UR - https://doi.org/10.1038/362841a0 DO - 10.1038/362841a0 ID - Kim1993 ER - TY - JOUR AU - Witte, L. AU - Hicklin, D. J. AU - Zhu, Z. AU - Pytowski, B. AU - Kotanides, H. AU - Rockwell, P. AU - Bohlen, P. PY - 1998 DA - 1998// TI - Monoclonal antibodies targeting theVEGFreceptor-2(Flk1/ KDR) as an anti-angiogenic therapeutic strategy JO - Cancer Metastasis Rev VL - 17 UR - https://doi.org/10.1023/A:1006094117427 DO - 10.1023/A:1006094117427 ID - Witte1998 ER - TY - JOUR AU - Wakeling, A. E. AU - Guy, S. P. AU - Woodburn, J. R. AU - Ashton, S. E. AU - Curry, B. J. AU - Barker, A. J. AU - Gibson, K. H. PY - 2002 DA - 2002// TI - ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy JO - Cancer Res VL - 62 ID - Wakeling2002 ER - TY - JOUR AU - Huang, S. AU - Armstrong, E. A. AU - Benavente, S. AU - Chinnaiyan, P. AU - Harari, P. M. PY - 2004 DA - 2004// TI - Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0562 DO - 10.1158/0008-5472.CAN-04-0562 ID - Huang2004 ER - TY - STD TI - Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BVL et al (2016) A small molecule inhibitor of PDK1/PLCγ1 interaction blocks breast and melanoma cancer cell invasion. Sci Rep 6(1). https://doi.org/10.1038/srep26142 ID - ref114 ER - TY - JOUR AU - Fauvel, B. AU - Yasri, A. PY - 2014 DA - 2014// TI - Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer JO - mAbs VL - 6 UR - https://doi.org/10.4161/mabs.29089 DO - 10.4161/mabs.29089 ID - Fauvel2014 ER - TY - JOUR AU - Párrizas, M. AU - Saltiel, A. R. AU - LeRoith, D. PY - 1997 DA - 1997// TI - Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways JO - J Biol Chem VL - 272 UR - https://doi.org/10.1074/jbc.272.1.154 DO - 10.1074/jbc.272.1.154 ID - Párrizas1997 ER - TY - JOUR AU - Sun, H. D. AU - Malabunga, M. AU - Tonra, J. R. AU - DiRenzo, R. AU - Carrick, F. E. AU - Zheng, H. AU - Berthoud, H. AU - McGuinness, O. P. AU - Shen, J. AU - Bohlen, P. AU - Leibel, R. L. AU - Kussie, P. PY - 2007 DA - 2007// TI - Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys JO - Am J Physiol Endocrinol Metab VL - 292 UR - https://doi.org/10.1152/ajpendo.00089.2006 DO - 10.1152/ajpendo.00089.2006 ID - Sun2007 ER - TY - JOUR AU - Loddo, M. AU - Kingsbury, S. R. AU - Rashid, M. AU - Proctor, I. AU - Holt, C. AU - Young, J. PY - 2009 DA - 2009// TI - Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer JO - Br J Cancer VL - 100 UR - https://doi.org/10.1038/sj.bjc.6604924 DO - 10.1038/sj.bjc.6604924 ID - Loddo2009 ER - TY - JOUR AU - Yeh, A. C. AU - Ramaswamy, S. PY - 2015 DA - 2015// TI - Mechanisms of cancer cell dormancy-another hallmark of cancer? JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/0008-5472.can-15-1370 DO - 10.1158/0008-5472.can-15-1370 ID - Yeh2015 ER - TY - JOUR AU - Massague, J. PY - 2004 DA - 2004// TI - G1 cell-cycle control and cancer JO - Nature VL - 432 UR - https://doi.org/10.1038/nature03094 DO - 10.1038/nature03094 ID - Massague2004 ER - TY - JOUR AU - Moreno-Lorenzana, D. AU - Avilés-Vazquez, S. AU - Sandoval Esquivel, M. A. AU - Alvarado-Moreno, A. AU - Ortiz-Navarrete, V. AU - Torres-Martínez, H. PY - 2016 DA - 2016// TI - CDKIs p18INK4cand p57Kip2are involved in quiescence of CML leukemic stem cells after treatment with TKI JO - Cell Cycle VL - 15 UR - https://doi.org/10.1080/15384101.2016.116097 DO - 10.1080/15384101.2016.116097 ID - Moreno-Lorenzana2016 ER - TY - JOUR AU - Zhang, B. AU - Strauss, A. C. AU - Chu, S. AU - Li, M. AU - Ho, Y. AU - Shiang, K. -. D. PY - 2010 DA - 2010// TI - Effective targeting of quiescent chronic Myelogenous leukemia stem cells by histone Deacetylase inhibitors in combination with Imatinib Mesylate JO - Cancer Cell VL - 17 UR - https://doi.org/10.1016/j.ccr.2010.03.011 DO - 10.1016/j.ccr.2010.03.011 ID - Zhang2010 ER - TY - JOUR AU - Becker, W. PY - 2017 DA - 2017// TI - A wake-up call to quiescent cancer cells – potential use of DYRK1B inhibitors in cancer therapy JO - FEBS J VL - 285 UR - https://doi.org/10.1111/febs.14347 DO - 10.1111/febs.14347 ID - Becker2017 ER - TY - JOUR AU - Pierce, G. B. AU - Wallace, C. PY - 1971 DA - 1971// TI - Differentiation of malignant to benign cells JO - Cancer Res VL - 31 ID - Pierce1971 ER - TY - JOUR AU - Schober, M. AU - Fuchs, E. PY - 2011 DA - 2011// TI - Tumor-initiating stem cells of squamous cell car- cinomas and their control by TGF-b and integrin/focal adhesion kinase (FAK) signaling JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1107807108 DO - 10.1073/pnas.1107807108 ID - Schober2011 ER - TY - JOUR AU - Siegle, J. AU - M. AU - Basin, A. AU - Sastre-Perona, A. AU - Yonekubo, Y. AU - Brown, J. AU - Sennett, R. AU - Rendl, M. AU - Tsirigos, A. AU - Carucci, J. A. AU - Schober, M. PY - 2014 DA - 2014// TI - SOX2 is a cancer-specific regulator of tumor initiating potential in cutaneous squamous cell carcinoma JO - Nat Commun VL - 5 UR - https://doi.org/10.1038/ncomms5511 DO - 10.1038/ncomms5511 ID - Siegle2014 ER - TY - JOUR AU - Brown, J. A. AU - Schober, M. PY - 2018 DA - 2018// TI - Cellular quiescence: how TGFβ protects cancer cells from chemotherapy JO - Mol Cell Oncol VL - 5 UR - https://doi.org/10.1080/23723556.2017.1413495 DO - 10.1080/23723556.2017.1413495 ID - Brown2018 ER - TY - JOUR AU - Romero, I. AU - Bast, R. C. PY - 2012 DA - 2012// TI - Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy JO - Endocrinology VL - 153 UR - https://doi.org/10.1210/en.2011-2123 DO - 10.1210/en.2011-2123 ID - Romero2012 ER - TY - JOUR AU - Deng, X. AU - Hu, J. AU - Cunningham, M. J. AU - Friedman, E. PY - 2014 DA - 2014// TI - Mirk kinase inhibition targets ovarian cancer ascites JO - Genes Cancer VL - 5 ID - Deng2014 ER - TY - JOUR AU - Druker, B. J. AU - Guilhot, F. AU - O’Brien, S. G. AU - Gathmann, I. AU - Kantarjian, H. AU - Gattermann, N. PY - 2006 DA - 2006// TI - Five-year follow-up of patients receiving Imatinib for chronic myeloid leukemia JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/nejmoa06286 DO - 10.1056/nejmoa06286 ID - Druker2006 ER - TY - JOUR AU - Holyoake, T. L. AU - Vetrie, D. PY - 2017 DA - 2017// TI - The chronic myeloid leukemia stem cell: stemming the tide of persistence JO - Blood VL - 129 UR - https://doi.org/10.1182/blood-2016-09-696013 DO - 10.1182/blood-2016-09-696013 ID - Holyoake2017 ER - TY - JOUR AU - Hamilton, A. AU - Helgason, G. V. AU - Schemionek, M. AU - Zhang, B. AU - Myssina, S. AU - Allan, E. K. PY - 2011 DA - 2011// TI - Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2010-12-32684 DO - 10.1182/blood-2010-12-32684 ID - Hamilton2011 ER - TY - JOUR AU - Karsli-Uzunbas, G. AU - Guo, J. Y. AU - Price, S. AU - Teng, X. AU - Laddha, S. V. AU - Khor, S. AU - Kalaany, N. Y. AU - Jacks, T. AU - Chan, C. S. AU - Rabinowitz, J. D. AU - White, E. PY - 2014 DA - 2014// TI - Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance JO - Cancer Discovery VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-14-0363 DO - 10.1158/2159-8290.CD-14-0363 ID - Karsli-Uzunbas2014 ER - TY - JOUR AU - Moreau, K. AU - Luo, S. AU - Rubinsztein, D. C. PY - 2010 DA - 2010// TI - Cytoprotective roles for autophagy JO - Curr Opin Cell Biol VL - 22 UR - https://doi.org/10.1016/j.ceb.2009.12.002 DO - 10.1016/j.ceb.2009.12.002 ID - Moreau2010 ER - TY - JOUR AU - Baquero, P. a. b. l. o. AU - Dawson, A. m. y. AU - Mukhopadhyay, A. r. u. n. i. m. a. AU - Kuntz, E. l. o. d. i. e. M. AU - Mitchell, R. e. b. e. c. c. a. AU - Olivares, O. r. i. a. n. n. e. AU - Ianniciello, A. n. g. e. l. a. AU - Scott, M. a. r. y. T. AU - Dunn, K. a. r. e. n. AU - Nicastri, M. i. c. h. a. e. l. C. AU - Winkler, J. e. f. f. r. e. y. D. AU - Michie, A. l. i. s. o. n. M. AU - Ryan, K. e. v. i. n. M. AU - Halsey, C. h. r. i. s. t. i. n. a. AU - Gottlieb, E. y. a. l. AU - Keaney, E. r. i. n. P. AU - Murphy, L. e. o. n. O. AU - Amaravadi, R. a. v. i. K. AU - Holyoake, T. e. s. s. a. L. AU - Helgason, G. V. i. g. n. i. r. PY - 2018 DA - 2018// TI - Targeting quiescent leukemic stem cells using second generation autophagy inhibitors JO - Leukemia VL - 33 UR - https://doi.org/10.1038/s41375-018-0252-4 DO - 10.1038/s41375-018-0252-4 ID - Baquero2018 ER - TY - JOUR AU - Imai, K. AU - Takaoka, A. PY - 2006 DA - 2006// TI - Comparing antibody and small-molecule therapies for cancer JO - Nat Rev Cancer VL - 6 UR - https://doi.org/10.1038/nrc191 DO - 10.1038/nrc191 ID - Imai2006 ER - TY - JOUR AU - Savage, D. a. v. i. d. G. AU - Antman, K. a. r. e. n. H. PY - 2002 DA - 2002// TI - Imatinib Mesylate — A New Oral Targeted Therapy JO - New England Journal of Medicine VL - 346 UR - https://doi.org/10.1056/NEJMra013339 DO - 10.1056/NEJMra013339 ID - Savage2002 ER - TY - JOUR AU - Herbst, R. S. AU - Fukuoka, M. AU - Baselga, J. PY - 2004 DA - 2004// TI - Gefitinib-a novel targeted approach to treating cancer JO - Nat Rev Cancer VL - 4 UR - https://doi.org/10.1038/nrc1506 DO - 10.1038/nrc1506 ID - Herbst2004 ER - TY - JOUR AU - Adler, M. J. AU - Dimitrov, D. S. PY - 2012 DA - 2012// TI - Therapeutic antibodies against cancer JO - Hematol Oncol Clin North Am VL - 26 UR - https://doi.org/10.1016/j.hoc.2012.02.013 DO - 10.1016/j.hoc.2012.02.013 ID - Adler2012 ER - TY - JOUR AU - Hsu, J. L. AU - Hung, M. C. PY - 2016 DA - 2016// TI - The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer JO - Cancer Metastasis Rev VL - 35 UR - https://doi.org/10.1007/s10555-016-9649-6 DO - 10.1007/s10555-016-9649-6 ID - Hsu2016 ER - TY - JOUR AU - Nami, B. AU - Maadi, H. AU - Wang, Z. PY - 2018 DA - 2018// TI - Mechanisms underlying the action and synergism of Trastuzumab and Pertuzumab in targeting HER2-positive breast Cancer JO - Cancers VL - 10 UR - https://doi.org/10.3390/cancers10100342 DO - 10.3390/cancers10100342 ID - Nami2018 ER - TY - JOUR AU - Salomon, D. S. AU - Brandt, R. AU - Ciardiello, F. AU - Normanno, N. PY - 1995 DA - 1995// TI - Epidermal growth factor-related peptides and their receptors in human malignancies JO - Crit Rev Oncol Hematol VL - 19 UR - https://doi.org/10.1016/1040-8428(94)00144 DO - 10.1016/1040-8428(94)00144 ID - Salomon1995 ER - TY - JOUR AU - Moradi-Kalbolandi, S. AU - Hosseinzade, A. AU - Salehi, M. AU - Merikhian, P. AU - Farahmand, L. PY - 2018 DA - 2018// TI - Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER JO - J Pharm Pharmacol VL - 70 UR - https://doi.org/10.1111/jphp.12911 DO - 10.1111/jphp.12911 ID - Moradi-Kalbolandi2018 ER - TY - JOUR AU - Camidge, D. R. AU - Pao, W. AU - Sequist, L. V. PY - 2014 DA - 2014// TI - Acquired resistance to TKIs in solid tumours: learning from lung cancer JO - Nat Rev Clin Oncol VL - 11 UR - https://doi.org/10.1038/nrclinonc.2014.104 DO - 10.1038/nrclinonc.2014.104 ID - Camidge2014 ER - TY - JOUR AU - Watanabe, M. AU - Kawaguchi, T. AU - Isa, S. I. AU - Ando, M. AU - Tamiya, A. AU - Kubo, A. PY - 2015 DA - 2015// TI - Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.ccr-14-2151 DO - 10.1158/1078-0432.ccr-14-2151 ID - Watanabe2015 ER - TY - JOUR AU - Kuiper, J. L. AU - Heideman, D. A. M. AU - Thunnissen, E. AU - Paul, M. A. AU - Wijk, A. W. AU - Postmus, P. E. AU - Smit, E. F. PY - 2014 DA - 2014// TI - Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients JO - Lung Cancer VL - 85 UR - https://doi.org/10.1016/j.lungcan.2014.03.016 DO - 10.1016/j.lungcan.2014.03.016 ID - Kuiper2014 ER - TY - JOUR AU - Hata, A. AU - Katakami, N. AU - Yoshioka, H. AU - Takeshita, J. AU - Tanaka, K. AU - Nanjo, S. PY - 2013 DA - 2013// TI - Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor JO - Cancer VL - 119 UR - https://doi.org/10.1002/cncr.28364 DO - 10.1002/cncr.28364 ID - Hata2013 ER - TY - JOUR AU - Denis, M. G. AU - Vallée, A. AU - Théoleyre, S. PY - 2015 DA - 2015// TI - EGFR T790M resistance mutation in non-small-cell lung carcinoma JO - Clin Chim Acta VL - 444 UR - https://doi.org/10.1016/j.cca.2015.01.039 DO - 10.1016/j.cca.2015.01.039 ID - Denis2015 ER - TY - JOUR AU - Yun, C. -. H. AU - Mengwasser, K. E. AU - Toms, A. V. AU - Woo, M. S. AU - Greulich, H. AU - Wong, K. -. K. PY - 2008 DA - 2008// TI - The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP JO - Proc Natl Acad Sci VL - 105 UR - https://doi.org/10.1073/pnas.0709662105 DO - 10.1073/pnas.0709662105 ID - Yun2008 ER - TY - JOUR AU - Graves-Deal, R. AU - Bogatcheva, G. AU - Rehman, S. AU - Lu, Y. AU - Higginbotham, J. N. AU - Singh, B. PY - 2019 DA - 2019// TI - Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer JO - Oncotarget VL - 10 UR - https://doi.org/10.18632/oncotarget.26663 DO - 10.18632/oncotarget.26663 ID - Graves-Deal2019 ER - TY - JOUR AU - Martin, M. J. AU - Eberlein, C. AU - Taylor, M. AU - Ashton, S. AU - Robinson, D. AU - Cross, D. PY - 2016 DA - 2016// TI - Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.13388 DO - 10.18632/oncotarget.13388 ID - Martin2016 ER - TY - STD TI - Bordi P, Tiseo M, Bortesi B, Naldi N, Buti S, Ardizzoni A (2014) Overcoming T790M- driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report. Tumori, 100:e20 ID - ref152 ER - TY - STD TI - Yeon HK, Ku M, Yang J (2019) Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer. Exp Mol Med 51(1). https://doi.org/10.1038/s12276-018-0202-2 ID - ref153 ER - TY - JOUR AU - Jiao, Q. AU - Bi, L. AU - Ren, Y. AU - Song, S. AU - Wang, Q. AU - Wang, Y. PY - 2018 DA - 2018// TI - Advances in studies of tyrosine kinase inhibitors and their acquired resistance JO - Mol Cancer VL - 17 UR - https://doi.org/10.1186/s12943-018-0801-5 DO - 10.1186/s12943-018-0801-5 ID - Jiao2018 ER - TY - JOUR AU - Azuma, K. AU - Hirashima, T. AU - Yamamoto, N. AU - Okamoto, I. AU - Takahashi, T. AU - Nishio, M. PY - 2016 DA - 2016// TI - Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib JO - ESMO Open VL - 1 UR - https://doi.org/10.1136/esmoopen-2016-000063 DO - 10.1136/esmoopen-2016-000063 ID - Azuma2016 ER - TY - JOUR AU - Wu, P. AU - Nielsen, T. E. AU - Clausen, M. H. PY - 2016 DA - 2016// TI - Small-molecule kinase inhibitors: an analysis of FDA-approved drugs JO - Drug Discov Today VL - 21 UR - https://doi.org/10.1016/j.drudis.2015.07.008 DO - 10.1016/j.drudis.2015.07.008 ID - Wu2016 ER - TY - JOUR AU - Mundi, P. S. AU - Sachdev, J. AU - McCourt, C. AU - Kalinsky, K. PY - 2016 DA - 2016// TI - AKT in cancer: new molecular insights and advances in drug development JO - Br J Clin Pharmacol VL - 82 UR - https://doi.org/10.1111/bcp.13021 DO - 10.1111/bcp.13021 ID - Mundi2016 ER - TY - JOUR AU - Clark, A. S. AU - West, K. AU - Streicher, S. AU - Dennis, P. A. PY - 2002 DA - 2002// TI - Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells JO - Mol Cancer Ther VL - 1 ID - Clark2002 ER - TY - JOUR AU - Zhang, J. AU - Yang, P. L. AU - Gray, N. S. PY - 2009 DA - 2009// TI - Targeting cancer with small molecule kinase inhibitors JO - Nat Rev Cancer VL - 9 UR - https://doi.org/10.1038/nrc2559 DO - 10.1038/nrc2559 ID - Zhang2009 ER - TY - JOUR AU - Pearce, L. R. AU - Komander, D. AU - Alessi, D. R. PY - 2010 DA - 2010// TI - The nuts and bolts of AGC protein kinases JO - Nat Rev Mol Cell Biol VL - 11 UR - https://doi.org/10.1038/nrm2822 DO - 10.1038/nrm2822 ID - Pearce2010 ER - TY - JOUR AU - Simard, J. R. AU - Getlik, M. AU - Grütter, C. AU - Pawar, V. AU - Wulfert, S. AU - Rabiller, M. AU - Rauh, D. PY - 2009 DA - 2009// TI - Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors JO - J Am Chem Soc VL - 131 UR - https://doi.org/10.1021/ja902010p DO - 10.1021/ja902010p ID - Simard2009 ER - TY - STD TI - Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW et al (2018) Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. https://doi.org/10.1021/acs.jmedchem.8b0104 ID - ref162 ER - TY - JOUR AU - Uhlenbrock, N. i. k. l. a. s. AU - Smith, S. t. e. v. e. n. AU - Weisner, J. ö. r. n. AU - Landel, I. n. a. AU - Lindemann, M. a. r. i. u. s. AU - Le, T. h. i. e. n. A. n. h. AU - Hardick, J. u. l. i. a. AU - Gontla, R. a. j. e. s. h. AU - Scheinpflug, R. e. b. e. k. k. a. AU - Czodrowski, P. a. u. l. AU - Janning, P. e. t. r. a. AU - Depta, L. a. u. r. a. AU - Quambusch, L. e. n. a. AU - Müller, M. a. t. t. h. i. a. s. P. AU - Engels, B. e. r. n. d. AU - Rauh, D. a. n. i. e. l. PY - 2019 DA - 2019// TI - Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt JO - Chemical Science VL - 10 UR - https://doi.org/10.1039/C8SC05212C DO - 10.1039/C8SC05212C ID - Uhlenbrock2019 ER - TY - JOUR AU - Ivaska, J. AU - Heino, J. PY - 2011 DA - 2011// TI - Cooperation between Integrins and growth factor receptors in signaling and endocytosis JO - Annu Rev Cell Dev Biol VL - 27 UR - https://doi.org/10.1146/annurev-cellbio-092910-15401 DO - 10.1146/annurev-cellbio-092910-15401 ID - Ivaska2011 ER - TY - JOUR AU - Xing, Z. AU - Chen, H. C. AU - Nowlen, J. K. AU - Taylor, S. J. AU - Shalloway, D. AU - Guan, J. L. PY - 1994 DA - 1994// TI - Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain JO - Mol Biol Cell VL - 5 UR - https://doi.org/10.1091/mbc.5.4.413 DO - 10.1091/mbc.5.4.413 ID - Xing1994 ER - TY - JOUR AU - Cruz da Silva, E. AU - Dontenwill, M. AU - Choulier, L. AU - Lehmann, M. PY - 2019 DA - 2019// TI - Role of Integrins in resistance to therapies targeting growth factor receptors in cancer JO - Cancers VL - 11 UR - https://doi.org/10.3390/cancers11050692 DO - 10.3390/cancers11050692 ID - Cruz da Silva2019 ER - TY - JOUR AU - Camorani, S. AU - Crescenzi, E. AU - Gramanzini, M. AU - Fedele, M. AU - Zannetti, A. AU - Cerchia, L. PY - 2017 DA - 2017// TI - Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep46659 DO - 10.1038/srep46659 ID - Camorani2017 ER - TY - JOUR AU - Laurenzana, A. AU - Margheri, F. AU - Biagioni, A. AU - Chillà, A. AU - Pimpinelli, N. AU - Ruzzolini, J. AU - Peppicelli, S. AU - Andreucci, E. AU - Calorini, L. AU - Serratì, S. PY - 2019 DA - 2019// TI - EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells JO - EBioMedicine VL - 39 UR - https://doi.org/10.1016/j.ebiom.2018.12.024 DO - 10.1016/j.ebiom.2018.12.024 ID - Laurenzana2019 ER - TY - JOUR AU - McArthur, G. A. AU - Chapman, P. B. AU - Robert, C. AU - Larkin, J. AU - Haanen, J. B. AU - Dummer, R. PY - 2014 DA - 2014// TI - Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/s1470-2045(14)70012-9 DO - 10.1016/s1470-2045(14)70012-9 ID - McArthur2014 ER - TY - JOUR AU - Smalley, K. S. M. PY - 2010 DA - 2010// TI - PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma JO - Curr Opin Investig Drugs VL - 11 ID - Smalley2010 ER - TY - STD TI - Talebi A, Dehairs J, Rambow F, Rogiers A, Nittner D, Derua R et al (2018) Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nat Commun 9(1). https://doi.org/10.1038/s41467-018-04664-0 ID - ref171 ER - TY - JOUR AU - Yarden, Y. AU - Pines, G. PY - 2012 DA - 2012// TI - The ERBB network: at last, cancer therapy meets systems biology JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3309 DO - 10.1038/nrc3309 ID - Yarden2012 ER - TY - JOUR AU - Stuhlmiller, T. J. AU - Miller, S. M. AU - Zawistowski, J. S. AU - Nakamura, K. AU - Beltran, A. S. AU - Duncan, J. S. PY - 2015 DA - 2015// TI - Inhibition of Lapatinib-induced Kinome reprogramming in ERBB2-positive breast Cancer by targeting BET family Bromodomains JO - Cell Rep VL - 11 UR - https://doi.org/10.1016/j.celrep.2015.03.037 DO - 10.1016/j.celrep.2015.03.037 ID - Stuhlmiller2015 ER - TY - STD TI - Yallowitz A, Ghaleb A, Garcia L, Alexandrova EM, Marchenko N (2018) Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. Cell Death Dis 9(6). https://doi.org/10.1038/s41419-018-0691-x ID - ref174 ER - TY - JOUR AU - Rahko, E. AU - Blanco, G. AU - Soini, Y. AU - Bloigu, R. AU - Jukkola, A. PY - 2003 DA - 2003// TI - A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients JO - Eur J Cancer VL - 39 UR - https://doi.org/10.1016/S0959-8049(02)00499-9 DO - 10.1016/S0959-8049(02)00499-9 ID - Rahko2003 ER - TY - JOUR AU - Koboldt, D. C. AU - Fulton, R. S. AU - McLellan, M. D. AU - Schmidt, H. AU - Kalicki-Veizer, J. AU - McMichael, J. F. PY - 2012 DA - 2012// TI - Comprehensive molecular portraits of human breast tumours JO - Nature VL - 490 UR - https://doi.org/10.1038/nature11412 DO - 10.1038/nature11412 ID - Koboldt2012 ER - TY - JOUR AU - Li, D. AU - Yallowitz, A. AU - Ozog, L. AU - Marchenko, N. PY - 2014 DA - 2014// TI - A gain-of-function mutant p53- HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress JO - Cell Death Dis VL - 5 UR - https://doi.org/10.1038/cddis.2014.158 DO - 10.1038/cddis.2014.158 ID - Li2014 ER - TY - JOUR AU - Corcoran, R. B. AU - Ebi, H. AU - Turke, A. B. AU - Coffee, E. M. AU - Nishino, M. AU - Cogdill, A. P. PY - 2012 DA - 2012// TI - EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with Vemurafenib JO - Cancer Dis VL - 2 UR - https://doi.org/10.1158/2159-8290.cd-11-0341 DO - 10.1158/2159-8290.cd-11-0341 ID - Corcoran2012 ER - TY - JOUR AU - Ahmed, T. A. AU - Adamopoulos, C. AU - Karoulia, Z. AU - Wu, X. AU - Sachidanandam, R. AU - Aaronson, S. A. AU - Poulikakos, P. I. PY - 2019 DA - 2019// TI - SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors JO - Cell Rep VL - 26 UR - https://doi.org/10.1016/j.celrep.2018.12.013 DO - 10.1016/j.celrep.2018.12.013 ID - Ahmed2019 ER -